Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution

GBI Research, May 2012, Pages: 129

GBI Research, the leading business intelligence provider, has released its latest research “Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution”. The report provides in-depth analysis of drivers and barriers that impact the global cardiovascular disorders market. The report analyzes the generics market for cardiovascular disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns are forecast until 2018 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The global generics market cardiovascular drugs is expected to grow rapidly due to the growing dyslipdemia, thrombosis and hypertension populations in the developed countries, as well as patent expiries of major blockbusters such as Lipitor (atorvastatin), Plavix (clopidigrel) and Diovan (valsartan). The patent expiries of these blockbuster drugs will trigger generic competition in the cardiovascular therapeutics market, making it more competitive.
In 2010, the generics market for cardiovascular drugs was estimated at $20.5 billion, indicating a year on year decline of 0.9% from 2004-2010. Patent expiries of the leading antiplatelets/antithrombotics such as Plavix (clopidigrel) and Lovenox (enoxaparin) and lipid lowering blockbuster Lipitor in 2010-2012, resulting in uptake of generics, is expected to cause the market to increase significantly from 2010 to 2018.

Scope

- Annualized market data for the generics in cardiovascular disorders market from 2004 to 2010, forecast forward to 2018.

- Analysis of the leading therapeutic segments, including pulmonary arterial hypertension, thrombosis, dyslipidemia, hypertension, coronary artery disease, and Angina Pectoris.

- Analysis of the generics in cardiovascular disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.

- Market characterization of the generics in cardiovascular disorders market, including market size, annual cost of treatment and treatment usage pattern.

- Key drivers and barriers that have a significant impact on the generics market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading generic companies. The key companies studied in this report are

- Key M&A activities, licensing agreements that have taken place from 2004 to 2011 in the global cardiovascular disorders market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1.1 List of Tables
1.2 List of Figures

2 Generics in Cardiovascular Diseases Market to 2018 – Introduction

3 Generics in Cardiovascular Diseases Market to 2018 - Global Market Overview
3.1 Introduction
3.1.1 Antidyslipidemics
3.1.2 Anti-Hypertensives
3.1.3 Rise in Generics in CVD Market
3.2 Revenue
3.3 Annual Cost of Therapy
3.4 Treatment Usage Patterns
3.4.1 Disease population
3.4.2 Treatment Seeking Population
3.4.3 Diagnosed Population
3.4.4 Prescription Population

4 Generics in Cardiovascular Disease Market to 2018 - Geographical Landscape
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.1.3 Treatment Usage Patterns
4.2 Top Five Countries of Europe
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Patterns
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Patterns

5 Generics in Cardiovascular Diseases Market to 2018- Therapeutic Landscape
5.1 Thrombosis
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Annual Cost of Therapy
5.1.4 Treatment Flow Algorithm
5.1.5 Treatment Usage Pattern
5.1.6 Drivers and Restraints
5.1.7 Drivers
5.1.8 Restraints
5.2 Pulmonary Arterial Hypertension
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Annual Cost of Therapy
5.2.4 Treatment Usage Patterns
5.2.5 Treatment Flow Algorithm
5.2.6 Drivers and Restraints
5.2.7 Drivers
5.2.8 Restraints
5.3 Hypertension
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Flow Algorithm for Hypertension
5.3.5 Treatment Usage Patterns
5.3.6 Drivers and Restraints
5.3.7 Drivers
5.3.8 Restraints
5.4 Dyslipidemia Market
5.4.1 Introduction
5.4.2 Revenue
5.4.3 Annual Cost of Therapy
5.4.4 Treatment Flow Algorithm
5.4.5 Treatment Usage Patterns
5.4.6 Drivers and Restraints
5.4.7 Drivers
5.4.8 Restraints
5.5 Coronary Artery Disease
5.5.1 Introduction
5.5.2 Revenue
5.5.3 Annual Cost of Therapy
5.5.4 Treatment Usage Patterns
5.5.5 Drivers and Restraints
5.5.6 Drivers
5.5.7 Restraints Market
5.6 Angina Pectoris Market
5.6.1 Introduction
5.6.2 Revenue
5.6.3 Cost of Therapy
5.6.4 Treatment Flow Algorithm
5.6.5 Treatment Usage Patterns
5.6.6 Drivers and Restraints
5.6.7 Drivers for the Angina Pectoris Market
5.6.8 Restraints for the Angina Pectoris Market

6 Generics in Cardiovascular Diseases Market to 2018 - Product Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline – Pulmonary Arterial Hypertension
6.1.2 Research and Development Pipeline – Dyslipidemia
6.1.3 Research and Development Pipeline – Coronary Artery Disease
6.1.4 Research and Development Pipeline – Angina Pectoris
6.1.5 Research and Development Pipeline – Thrombosis
6.1.6 Research and Development Pipeline – Hypertension

7 Generics in Cardiovascular Diseases Market to 2018 - Most Promising Pipeline Molecules
7.1 Eliquis
7.1.1 Introduction
7.1.2 Mechanism of Action
7.2 RG1658 (Dalcetrapib, JTT-705, RO4607381)
7.2.1 Introduction
7.2.2 Mechanism of Action
7.2.3 Clinical Trial Management 1
7.3 MK-0524A (Cordaptive, niacin + laropiprant)
7.3.1 Introduction
7.3.2 Mechanism of Action
7.3.3 Clinical Trial Management 2
7.4 AMR101 (LAX-101, Miraxion)
7.4.1 Introduction
7.4.2 Mechanism of Action
7.4.3 Clinical Trial Management 3

8 Generics in Cardiovascular Diseases Market to 2018 – Competitive Landscape
8.1 Teva Pharma
8.2 Sandoz
8.3 Actavis
8.4 Apotex
8.5 Watson Pharmaceuticals
8.5.1 Watson Launches First Generic Lipitor (atorvastatin)
8.6 Mylan

9 Generics in Cardiovascular Diseases Market to 2018 – Strategic Consolidations
9.1 Merger and Acquisition Deals (2004-2011)
9.1.1 Deals by Year
9.1.2 M&A Deals by Region
9.1.3 M&A Deals by Value
9.1.4 Deal Summary of Top 10 M&A Deals by Value
9.2 Licensing Deals
9.2.1 Deals by Indication
9.2.2 Deals by Geography
9.2.3 Deals by Year
9.2.4 Deal Summary of Top Five Licensing Deals by Value
9.3 Co-development Deals
9.3.1 Deals by Indication
9.3.2 Deals by Geography
9.3.3 Deals by Year
9.3.4 Deal Summary of Top Five Co-development Deals by Value

10 Generics in Cardiovascular Diseases Market to 2018 - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Sources
10.4 Research Methodology
10.4.1 Coverage
10.4.2 Secondary Research
10.4.3 Primary Research
10.4.4 The report consists of the following four major sections
10.4.5 Therapeutic Landscape
10.4.6 Forecasting Model for Therapeutic Areas
10.4.7 Geographical Landscape
10.4.8 Pipeline Analysis
10.4.9 Competitive Landscape
10.4.10 Expert Panel Validation
10.5 Contact Us
10.6 Disclaimer

1.1 List of Tables
Table 1: Generics in Cardiovascular Diseases Market, Patent Expiries of Leading Cardiovascular Drugs, 2011
Table 2: Generics in Cardiovascular Diseases Market, Global, Revenue ($bn), 2004–2010
Table 3: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn), 2010–2018
Table 4: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($), 2004–2010
Table 5: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($), 2010–2018
Table 6: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million), 2004–2010
Table 7: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million), 2010–2018
Table 8: Generics in Cardiovascular Diseases Market, The US, Revenue ($bn), 2004–2010
Table 9: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn), 2010–2018
Table 10: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($), 2004–2010
Table 11: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($), 2010–2018
Table 12: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns (million), 2004–2010
Table 13: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns (million), 2010–2018
Table 14: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue ($bn), 2004–2010
Table 15: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2010–2018
Table 16: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost of Therapy($), 2004–2010
Table 17: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010–2018
Table 18: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2004–2010
Table 19: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2010–2018
Table 20: Generics in Cardiovascular Diseases Market, Japan, Revenue ($bn), 2004–2010
Table 21: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($bn), 2010–2018
Table 22: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($), 2004–2010
Table 23: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($), 2010–2018
Table 24: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns (million), 2004–2010
Table 25: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns (million), 2010–2018
Table 26: Generics in Thrombosis Market, Global, Revenue ($m), 2004–2010
Table 27: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2010–2018
Table 28: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2010
Table 29: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2010–2018
Table 30: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–2010
Table 31: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2010–2018
Table 32: Generics in Pulmonary Arterial Hypertension Market, Global Revenue ($m), 2004–2010
Table 33: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m), 2010–2018
Table 34: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2010
Table 35: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy ($), 2010–2018
Table 36: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns, (‘000), 2004–2010
Table 37: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns, (‘000), 2010–2018
Table 38: Generics in Hypertension Market, Global, Revenue ($bn), 2004–2010
Table 39: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2010–2018
Table 40: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2010
Table 41: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2010–2018
Table 42: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2004–2010
Table 43: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2010–2018
Table 44: Generics in Dyslipidemia Market, Global, Revenue ($bn), 2004–2010
Table 45: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2010–2018
Table 46: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2010
Table 47: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2010–2018
Table 48: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2004–2010
Table 49: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2010–2018
Table 50: Generics in Coronary Artery Disease Market, Global, Revenue ($m), 2004–2010
Table 51: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m), 2010–2018
Table 52: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($), 2004–2010
Table 53: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($), 2010–2018
Table 54: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million), 2004–2010
Table 55: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million), 2010–2018
Table 56: Generics in Angina Pectoris Market, Global, Revenue ($m), 2004–2010
Table 57: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($m), 2010–2018
Table 58: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2010
Table 59: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2010–2018
Table 60: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million), 2004–2010
Table 61: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million), 2010–2018
Table 62: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in PAH, 2011
Table 63: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Regulatory and Phase III Research and Development Pipeline, 2011
Table 64: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase II Research and Development Pipeline, 2011
Table 65: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Phase I Research and Development Pipeline, 2011
Table 66: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia, Pre-Clinical and Discovery Research and Development Pipeline, 2011
Table 67: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in CAD, 2011
Table 68: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Angina Pectoris, 2011
Table 69: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Thrombosis (%), 2011
Table 70: Generics in Cardiovascular Diseases Market, Global, Hypertension Regulatory Filing and Phase III Research and Development Pipeline, 2011
Table 71: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase II Research and Development Pipeline, 2011
Table 72: Generics in Cardiovascular Diseases Market, Global, Hypertension Phase I Research and Development Pipeline, 2011
Table 73: Generics in Cardiovascular Diseases Market, Global, Hypertension Pre-clinical and Discovery Research and Development Pipeline, 2011
Table 74: Generics in Cardiovascular Diseases Market, Global, M&A Deals, 2010-2011
Table 75: Generics in Cardiovascular Diseases Market, Global, Licensing Deals, 2010–2011

1.2 List of Figures
Figure 1: Generics in Cardiovascular Diseases Market, Global, Revenue Forecasts ($bn), 2004–2018
Figure 2: Generics in Cardiovascular Diseases Market, Global, Annual Cost of Therapy($), 2004–2018
Figure 3: Generics in Cardiovascular Diseases Market, Global, Treatment Usage Patterns (million), 2004–2018
Figure 4: Generics in Cardiovascular Diseases Market, The US, Revenue Forecasts ($bn), 2004–2018
Figure 5: Generics in Cardiovascular Diseases Market, The US, Annual Cost of Therapy($), 2004–2018
Figure 6: Generics in Cardiovascular Diseases Market, The US, Treatment Usage Patterns (million), 2004–2018
Figure 7: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2004–2018
Figure 8: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Annual Cost of Therapy($), 2004–2018
Figure 9: Generics in Cardiovascular Diseases Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2004–2018
Figure 10: Generics in Cardiovascular Diseases Market, Japan, Revenue Forecasts ($m), 2004–2018
Figure 11: Generics in Cardiovascular Diseases Market, Japan, Annual Cost of Therapy ($), 2004–2018
Figure 12: Generics in Cardiovascular Diseases Market, Japan, Treatment Usage Patterns (million), 2004–2018
Figure 13: Generics in Thrombosis Market, Global, Revenue Forecasts ($m), 2004–2018
Figure 14: Generics in Thrombosis Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 15: Generics in Cardiovascular Diseases Market, Global, Thrombosis, Treatment Flow Algorithm
Figure 16: Generics in Thrombosis Market, Global, Treatment Usage Pattern (million), 2004–2018
Figure 17: Generics in Thrombosis Market, Global, Drivers and Restraints, 2011
Figure 18: Generics in Pulmonary Arterial Hypertension Market, Global, Revenue Forecasts ($m), 2004–2018
Figure 19: Generics in Pulmonary Arterial Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 20: Generics in Pulmonary Arterial Hypertension Market, Global, Treatment Usage Patterns, (‘000), 2004–2018
Figure 21: Generics in Cardiovascular Diseases Market, Global, Pulmonary Arterial Hypertension, Treatment Flow Algorithm, 2010
Figure 22: Generics in Pulmonary Arterial Hypertension, Global, Drivers and Restraints, 2011
Figure 23: Generics in Hypertension Market, Global, Revenue Forecasts ($bn), 2004–2018
Figure 24: Generics in Hypertension Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 25: Generics in Cardiovascular Diseases Market, Global, Hypertension, Treatment Flow Algorithm, 2011
Figure 26: Generics in Hypertension Market, Global, Treatment Usage Pattern (million), 2004–2018
Figure 27: Generics in Hypertension Market, Global, Drivers and Restraints, 2010
Figure 28: Generics in Dyslipidemia Market, Global, Revenue Forecasts ($bn), 2004–2018
Figure 29: Generics in Dyslipidemia Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 30: Generics in Cardiovascular Diseases Market, Dyslipidemia, Treatment Flow Algorithm
Figure 31: Generics in Dyslipidemia Market, Global, Treatment Usage Pattern (million), 2004–2018
Figure 32: Generics in Dyslipidemia Market, Global, Drivers and Restraints, 2010
Figure 33: Generics in Coronary Artery Disease Market, Global, Revenue Forecasts ($m), 2004–2018
Figure 34: Generics in Coronary Artery Disease Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 35: Generics in Coronary Artery Disease Market, Global, Treatment Usage Pattern (million), 2004–2018
Figure 36: Generics in Coronary Artery Disease Market, Global, Drivers and Restraints, 2011
Figure 37: Generics in Angina Pectoris Market, Global, Revenue Forecasts ($bn), 2004–2018
Figure 38: Generics in Angina Pectoris Market, Global, Annual Cost of Therapy ($), 2004–2018
Figure 39: Generics in Cardiovascular Diseases Market, Global, Angina Pectoris, Treatment Flow Algorithm
Figure 40: Generics in Angina Pectoris Market, Global, Treatment Usage Pattern (million), 2004–2018
Figure 41: Generics in Angina Pectoris Market, Global, Drivers and Restraints, 2011
Figure 42: Generics in Cardiovascular Diseases Market, Global Product Pipeline by Indication (%), 2011
Figure 43: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in PAH (%), 2011
Figure 44: Generics in Cardiovascular Diseases Market, Global, Dyslipidemia Research and Development Pipeline by Phase (%), 2011
Figure 45: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in CAD (%), 2011
Figure 46: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Thrombosis (%), 2011
Figure 47: Generics in Cardiovascular Diseases Market, Global, Research and Development Pipeline by Phase in Hypertension (%), 2011
Figure 48: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Year, 2004–2011
Figure 49: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Geography, 2004–2011
Figure 50: Generics in Cardiovascular Diseases Market, Global, M&A Deals by Value ($m), 2004–2010
Figure 51: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Indication (%), 2004–2011
Figure 52: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Geography (%), 2004–2011
Figure 53: Generics in Cardiovascular Diseases Market, Global, Licensing Deals by Year, 2004–2011
Figure 54: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Indication (%), 2004-2011
Figure 55: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Geography (%), 2004–2010
Figure 56: Generics in Cardiovascular Diseases Market, Global, Co-development Deals by Year, 2004-2011
Figure 57: GBI Research Market Forecasting Model

- Teva Pharma
- Sandoz
- Actavis
- Apotex
- Watson Pharmaceuticals
- Mylan"

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

This title is also available in the following language

• Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution (English Version)

Customers who bought this item also bought

• Cardiovascular Partnering Terms and Agreements
• CNS Therapeutics - Global Strategic Business Report
• The Impact of Generics on Pharmaceutical Growth Opportunities - A Growing Threat that Offers Future Opportunities
• Regenerative Medicine - Global Strategic Business Report
• The Incidence and Prevalence Database: Global Incidence, Prevalence, Morbidity, Comorbidity, Cost Data, Symptoms and Many Other Health Issues for over 4,500 Diseases and Procedures
• World Vaccines Market: Vaccine Segments Analysis, Vaccine Cases and Future Forecast
• Nuclear Medicine - Global Strategic Business Report
• Pediatric Drugs and Vaccines - Global Business Strategic Report
• Ion Channel Modulators - Global Strategic Business Report
• Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region